研究单位：[1]Shanghai Junshi Bioscience Co.,Ltd.[2]Beijing Cancer Hospital,Beijing,Beijing,China,100142[3]The General Hospital of the People's Liberation Army (PLAGH),Beijing,Beijing,China,100853[4]Fujian Medical University Union Hospital Fuzhou,Fujian,China,350001[5]Sun Yat-sen University[6]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology,Wuhan,Hubei,China,430030[7]Southern Medical University Nanfang Hospital,Guangzhou,Guangdong,China
研究目的：
The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and neck squamous cell carcinoma and to determine the recommended phase II dose (RP2D)
